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AbstrAct
background Death not directly due to cancer has been 
termed ‘treatment-related mortality’ (TRM). Appreciating 
the differences between TRM and disease-related death is 
critical in directing strategies to improve supportive care, 
interventions delivered or disease progression. Recently, a 
global collaboration developed and validated a consensus-
based classification tool and attribution system.
Objectives To evaluate the reliability of the newly developed 
consensus-based definition of TRM and explore the use of 
the cause-of-death attribution system outside the centre it 
was initially validated (Toronto, Canada). In the initial study, 
reviewers listed multiple causes of death. In this study, 
reviewers identified a primary cause for simplicity.
setting The paediatric haematology and oncology 
department at Leeds Teaching Hospital in Leeds, UK.
Participants Two consultants and two clinical research 
associates (CRAs).
Methods Thirty medical records of the most recent deaths 
in children with cancer, 2 and 4 weeks prior to death, were 
anonymised and presented to the participants. Reviewers 
independently classified deaths as ‘treatment related 
mortality’ or ‘not treatment related’ according to the algorithm 
developed. When TRM occurred, reviewers applied the cause-
of-death attribution system to identify the primary cause of 
death. Inter-relater reliability was assessed using the kappa 
statistic (k).
Main outcome Inter-relater reliability between CRA and 
consultants.
results Reliability of the classification was deemed ‘very 
good’ between CRA and consultants (k=0.86, 95% CI 0.72 to 
0.97). Ten deaths were classified as TRM, of which infection 
was the most frequent cause identified. Reviewers disagreed 
on the primary cause of death (eg, respiratory vs infection) 
when applying the cause-of-death attribution system in six 
cases and probable and possible causes in four cases. The 
study identified how the algorithm may not detect TRM in 
patients receiving non-curative therapy.
conclusions The classification and cause of death 
attribution system could be implemented in different 
healthcare settings. Adaptation of the classification tool in 
patients receiving non-curative interventions and the cause of 
death attribution system should be considered.
bAckgrOund
Survival of children diagnosed with malig-
nancies has improved with recent estimates 
suggesting more than 80% of those diagnosed 
in high-income countries will survive.2 This 
still means 20% of children will die—around 
80 000 deaths worldwide in 2012.2 The cause 
of death may be due directly to the disease, 
or complications or toxicities of interventions 
delivered. The increasing success of cancer-di-
rected interventions has contributed to a 
higher relative proportion of deaths due to 
associated toxicities.3 Death not directly due 
to the cancer has been broadly termed ‘treat-
ment-related mortality’ (TRM). This includes 
death from infection, bleeding and organ 
dysfunction.4 Incidence varies according to 
the underlying disease, stage of treatment 
and socioeconomic status.5 Identifying the 
nature of the mortality is critical in helping 
researchers and clinicians improve survival in 
particular diagnostic groups by focusing on 
strategies to improve supportive care when 
death is predominantly through TRM.
Despite the importance of TRM, varying 
definitions have been used. Systematic 
reviews6 7 identified significant heteroge-
neity in TRM definitions used in randomised 
trials. This inspired a global collaboration 
to develop a consensus-based classification 
tool for ascribing death as TRM, and further 
What this study hopes to add?
 ► The classification tool is not designed to detect TRM 
in patients receiving non-curative therapy.
 ► The classification and cause of death attribution 
system can be used in different healthcare settings.
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Original article
What is already known on this topic?
 ► Treatment-related mortality (TRM) is poorly defined 
in paediatric oncology and haematology.
 ► A global collaboration developed and validated a 
consensus-based classification tool and attribution 
system (in Toronto, Canada).
2 Hassan H, et al. BMJ Paediatrics Open 2017;1:e000082. doi:10.1136/bmjpo-2017-000082
Open Access
Figure 1 Classification of TRM in children with cancer, taken from.7 TRM, treatment-related mortality.
specific attribution of cause of death,1 primarily to be 
used by clinical research associates (CRAs). Reliability for 
the TRM classification was ‘very good’ between medical 
and CRA reviewers that had been involved in developing 
the system (kappa=0.92, 95% CI 0.78 to 1.00).1
An ideal classification system for TRM should be appli-
cable across different countries, treatment protocols 
and healthcare settings. To assess this, it is important to 
attempt to further validate the classification and attri-
bution system in a different setting, with professionals 
uninvolved in the development of the system. This paper 
reports such validation at a large regional paediatric 
oncology centre in a different continent to the one in 
which the system was originally developed. In the original 
study, reviewers attributed death to multiple probable or 
possible causes. While developing the study protocol, we 
decided to limit the number of causes of death to one 
primary probable or possible cause for simplicity.
Objectives
This study aimed to evaluate the reliability of the newly 
developed consensus-based definition of TRM and 
explore the use of the cause-of-death attribution system 
at a regional paediatric oncology centre in Leeds, 
England. In the initial study, reviewers listed multiple 
causes of death. However, in this study, reviewers identi-
fied a primary cause for simplicity.
MethOds
Eligible patient records were those of patients treated 
for a malignancy or who underwent a haematopoietic 
stem cell transplant (HSCT) for a non-malignant diag-
nosis at Leeds Children’s Hospital (Leeds, UK) while 
aged 18 years or younger at diagnosis. Five cases were 
excluded as patients had died following relapse after the 
age of 18 years or the medical records were not located. 
All included patients died between 2014 and 2016. 
Thirty patient records were included. Copies of the clin-
ical records, with information from both 2 weeks prior 
to death and with the information extending back to 4 
weeks prior to death, were anonymised. This resulted in 
60 sets of anonymised case notes (30 patients, each with 
two time periods), which were presented in a different 
random order for each assessor. Four participants were 
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Table 1 Summary of kappa statistic (k) and 95% CIs of independent reviewers, consultants, CRAs and between CRA and 
consultants for all total case reviews, 4 weeks and 2 weeks prior to death using the cause of death attribution system
Inter-rater comparison Total k (95% CI) 4 weeks k (95% CI) 2 weeks k (95% CI)
Independent reviewers* 0.92 (0.83 to 0.98) 0.91 (0.76 to 1.00) 0.92 (0.79 to 1.00)
Consultants† 0.85 (0.67 to 0.97) 0.85 (0.59 to 1.00) 0.84 (0.59 to 1.00)
CRA† 0.96 (0.87 to 1.00) 0.85 (0.59 to 1.00) 0.85 (0.60 to 1.00)
CRA versus consultants† 0.86 (0.72 to 0.97) 0.87 (0.66 to 1.00) 0.86 (0.67 to 1.00)
*Calculated using the Fleiss’ kappa statistic (between four reviewers).
†Calculated using the Cohen’s kappa statistic (between two reviewers or two groups).
CRA, clinical research associates.
identified to review the case notes; the two CRAs were a 
data analyst (AF) and research nurse (JT), and the two 
senior clinicians were a consultant paediatric oncolo-
gist and consultant paediatric haematologist (AWG and 
SEK).
The study was undertaken on a single afternoon. 
After agreeing and signing a consent form, participants 
received a 10 min educational presentation explaining 
how to use the system and how the study would be under-
taken. The reviewers then independently classified each 
death according to the algorithm (figure 1). For cases 
assessed as TRM, the reviewers were asked to apply the 
cause-of-death attribution system (online supplementary 
file 1) to identify a primary cause of death. Following the 
individual completion of the assessments, a moderated 
group discussion was undertaken with notes recorded by 
two facilitators and used to supplement the themes of the 
discussion.
Inter-relater reliability was assessed using the kappa 
statistic (k). Criterion validity was assessed by assuming 
classification by the consultants as the gold standard. 
Group consensus classification between and within the 
CRAs and consultant group was evaluated using the 
Cohen’s kappa statistic and across all individuals using 
the Fleiss’ kappa statistic. The strength of agreement was 
defined as slight (0.00–020), fair (0.21–0.40), moderate 
(0.41–0.60), good (0.61–0.80) and very good (0.81–
1.00).8 A numerical code was used to combine agree-
ment/disagreement between the individual consultants 
(TRM was recorded as ‘0’ and non-TRM outcomes were 
recorded as ‘1’ in Excel). When calculating inter-relater 
reliability between the CRAs and consultants if indi-
vidual disagreement was recorded, then the outcome 
was recorded as ‘2’. Based on the previously published 
study,1 we decided to include 30 cases for analysis. A 
sample size of 27 deaths determined whether k was good 
(ie, ≥0.61), with a power of 0.80, and two-sided α of 0.05 
and assuming that TRM accounted for 20% of deaths.7 
A further 30 cases would be reviewed if validity was inad-
equate (defined a priori as k<0.6). Calculation of the k 
statistic was completed using the R studio irr package, 
and a bootstrap with 200 iterations was used to calculate 
95% CIs.9 Comparison of cause of death was qualitative, 
and to provide further insight, reviewers participated in a 
discussion of the use of the algorithm and cause of death 
attribution system.
results
demographics
Age of identified patients ranged from less than 1–17 
years and 57% (17) were male. Sixty-seven per cent (20) 
were diagnosed with solid tumours, and 33% (10) were 
diagnosed with malignant haematological conditions. 
Collectively, sarcomas were the most frequent solid 
tumour diagnosed (12 cases, 40% of total), followed by 
central nervous system (CNS) tumours (nine cases, 30% 
of total). Twenty-seven per cent (eight cases) of these 
patients had presented with metastatic disease at diag-
nosis. All patients with malignant haematological condi-
tions were diagnosed with leukaemia. Forty per cent (12 
cases) of patients had either received a transplant or 
presented with relapsed disease. A summary is enclosed 
in online supplementary file 2.
classification of trM
Ten deaths (33%) were identified as TRM by at least one 
reviewer. Fifteen per cent (3/20) of patients diagnosed 
with solid tumours, and 80% (8/10) of patients diag-
nosed with malignant haematological conditions who 
died were classified as TRM. Reliability of classification 
was very good between CRAs and consultants, with a 
kappa statistic of 0.86 (95% CI 0.72 to 0.97, with disa-
greement on three deaths). There was also very good 
agreement between CRAs (k=0.96, 95% CI 0.87 to 1.00, 
disagreement on one record) and between consultants 
(k=0.85, 95% CI 0.67 to 0.97, with disagreement on two 
deaths) (see table 1).
When the 2-week and 4-week data were examined, 
there was no difference between the assessments of each 
of the four assessors (see table 1).
cause of death attribution system
Table 2 summarises the diagnoses of the 10 patients 
whose deaths were classified as TRM, alongside the 
cause of death as attribution by each assessor.
In brief, there was unanimous agreement on cause 
of death of three cases (J, V and AA); the other seven 
cases has inconsistencies in either the nature of cause of 
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Table 2 Summary of cause of death attribution by reviewers for deaths classified as TRM
Case Diagnosis CRA 1 CRA 2 Consultant 1 Consultant 2
J AML prior to HSCT Immunomediated Immunomediated Immunomediated Immunomediated
M ATRT Acute symptomatic 
intracranial 
haemorrhage
Acute symptomatic 
intracranial 
haemorrhage
Not reported Acute symptomatic 
intracranial 
haemorrhage
V AML Infection Infection Infection Infection
X B cell ALL Acute symptomatic 
intracranial 
haemorrhage
Acute symptomatic 
intracranial 
haemorrhage
Infection Infection
Y T cell ALL Respiratory Infection Acute symptomatic 
intracranial 
haemorrhage
Infection
Z B cell ALL Respiratory Infection Respiratory Infection
AA B cell ALL Infection Infection Infection Infection
AB Ependymoma Not reported Infection Not reported Infection
AC T cell ALL Worsening 
symptomatic graft 
versus host disease
Worsening 
symptomatic graft 
versus host disease
Worsening 
symptomatic graft 
versus host disease
Acute symptomatic 
pulmonary 
haemorrhage
AD B cell ALL post-
HSCT
Unclear Difficult case Worsening 
symptomatic graft 
versus host disease
Acute kidney Injury
Bold font=probable causes of death.
ALL, acute lymphoblastic leukaemia; AML, acute myeloid lukemia; ATRT, atypical teratoid rhabdoid tumour; CRA, clinical research associates; 
HSCT, haematopoietic stem cell transplant; TRM, treatment-related mortality.
death (eg, infection vs immune mediated) or strength 
of evidence (ie, probable vs possible). In one complex 
scenario (AD), the CRAs did not feel able to record a 
cause of death.
Postreview discussion
The reviewers all agreed that the algorithm was straight-
forward to use and that it would be beneficial to have a 
standardised tool and attribution system to use in trials 
nationally and globally.
Three difficulties with the system were identified: first, 
how to address the patients who may die from TRM while 
receiving non-curative therapy and particularly how the 
algorithm could be used as part of palliative care trial. In 
one particular case, a patient taking palliative etoposide 
following a diagnosis of relapsed ALL developed a febrile 
illness and died. Second, how should deaths in children 
after the completion of treatment be classified? A child 
(case V) who had completed treatment for standard risk 
AML died of overwhelming pneumococcal septicaemia 6 
months after end of treatment while in complete remis-
sion. Another further case the assessors had difficulty 
with (case M) followed presentation acutely with signs of 
raised intracranial pressure and large mass noted on CT. 
This patient died on the operating table while receiving 
surgical intervention.
Attribution of cause of death was felt to be more difficult 
than ascribing a death as TRM or not. The case the reviewers 
felt was most difficult to assign was patient who died of 
multiorgan failure following a HSCT (AD); both CRAs inde-
pendently decided to not attribute a cause of death.
discussiOn
This study is, to the best of our knowledge, the first reval-
idation of the standardised definition of TRM and cause 
of death attribution system for patients with paediatric 
cancer.1 It demonstrates that the system is reliable and 
established its validity in an alternative centre and health-
care system with different treatment protocols. It can be 
used after very limited training, with ‘very good’ agree-
ment between assessors irrespective of discipline (Fleiss’ 
kappa 0.92, 95% CI 0.83 to 0.98). The study confirms the 
observations of the development group and shows that 
information from 2 weeks prior to the death of a patient 
is sufficient to consistently attribute death to TRM or 
disease.
Although consultants’ opinions are considered 
gold standard, in this study we identified how even expe-
rienced clinicians may disagree on use of the algorithm. 
Consultants disagreed on the classification of death in 
two cases; this may have occurred due to the individual 
consultant’s clinical experience or previous contact with 
the patients. Even though the cases were anonymised 
and randomised, the physicians may have recognised 
the patient due to their potential clinical involvement 
in direct patient care. The differences identified high-
light how the TRM classification tool is unlikely to ever 
have perfect agreement between reviewers irrespective of 
experience, and clinical, scientific knowledge.
In this study, reviewers attributed death to one primary 
probable, or possible, cause. While developing the study 
protocol, we decided to limit the number of causes of 
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Figure 2 Proposed classification of TRM in children 
receiving non-curative therapy (NCT) only. TRM, treatment-
related mortality.
death for simplicity. However, reviewers found it chal-
lenging to identify only one cause of death and distin-
guish between probable and possible causes. In the 
original study, reviewers attributed death to multiple 
probable or possible causes. Despite this difference, 
reviewers only agreed on the causes of death on three of 
nine cases classified as TRM. This is similar to the results 
in this study of which reviewers agreed on 3 of 10 cases.
Since the development of this study, a standard oper-
ating procedure TRM web-based tool has been published 
(https://www. sungresearch. com/ trm- training- manual/) 
and includes working examples. Use of this tool when 
delivering the training package should help clarify 
how to use the cause-of-death attribution system and 
minimise misunderstanding. Currently, the web-based 
tool is available in English; having the tool available in 
other languages could potentially reduce confusion and 
improve harmonisation across clinical trials.
Our study highlights specific challenges with the 
system as it currently exists, both with the classification 
of TRM and the attribution of a specific cause of death. 
Fundamentally, this approach defines deaths as either 
‘treatment related’ or ‘cancer related’. This gives rise 
to a semantic challenge; ‘treatment-related mortality’ 
implies that deaths that come under this term occur 
directly because of the therapies delivered. However, 
the classification system classifies deaths that occur 
prior to commencement of anticancer therapy that are 
not directly attributable to the cancer (eg, tumour lysis 
syndrome in high-count leukaemia) as cases of TRM. This 
clash of language and ‘common sense’ may confuse users 
of the classification tool, for example, case M in which a 
patient presented acutely with signs of raised intracranial 
pressure and died on the operating table.
A deeper challenge to this system addressed the phil-
osophical distinction of assigning all deaths into one of 
two categories: cancer or treatment related. There is a 
convincing argument that a third category of death 
should be attributable, ‘other non-cancer death’, for 
those who die of an event or illness external to their 
malignancy. This problem is particularly evident if the 
current system is to be used after the completion of treat-
ment. For example, a patient dies as a passenger in an 
air traffic accident, 4 years after treatment for a localised 
Wilms tumour. In the current system, this death is classi-
fied as TRM, even though the death is unrelated to the 
child’s cancer diagnosis.
Conversely, it is also important to note how a diagnosis 
of cancer may be included in ‘non-cancer deaths’. For 
example, a patient may commit suicide some years after 
the completion of treatment because of the psychological 
effects of their diagnosis or treatment. Any addition to 
the system would need to be sensitive to these potential 
issues.
We have identified the need to further refine the 
approach to categorising cause of death in patients 
with cancer receiving care without intent to cure. 
This is particularly important if the system is applied 
in ‘routine’ settings, assessing deaths in the palliative 
setting rather than in the original setting of use within 
a curative trial. Increasingly, individuals destined not to 
be cured are living for lengthier periods due to partic-
ipation in clinical trials/studies. This group of patients 
currently have all deaths classified as ‘not treatment-re-
lated mortality’ as clinicians would have specified 
progressive disease or that cancer therapy has no cura-
tive intent. This algorithm may fail to identify a signifi-
cant group of patients who may die of causes amenable 
to better supportive care while receiving palliative 
care. For example, a patient can die of overwhelming 
sepsis while receiving palliative etoposide for refractory 
neuroblastoma. This could be addressed by modifying 
the algorithm, for this type of use. Another proposal 
includes using a separate classification tool for patients 
on non-curative therapy trials (figure 2), although this 
should be further developed in conjunction with palli-
ative care physicians and researchers. The counterar-
gument to this suggested change is the risk of adding 
complexity to a simple, effective tool that can be used 
by people of different skills and healthcare settings 
globally. It will also have similar issues with interpreta-
tion as with initial algorithm.
Reviewers failed to agree on a primary cause of death 
in six episodes and probable and possible causes in four 
cases. Differences in cause of death allocated could be 
attributed to the reviewers’ previous experience, clin-
ical expertise and interpretation of the clinical records, 
particularly in light of potential previous direct clinical 
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involvement with the cases under review. Currently, the 
tool is intended for use by any CRA; however, it may 
require users to have a certain level of experience or 
clinical expertise, and agreement may be reduced with 
CRA who are new to the role.
Understanding and interpretation of the system as 
proposed for attribution of a specific mechanistic cause 
of death could potentially be improved by dedicating 
more time during the presentations and using the 
newly developed web-based training tool. Alternatively, 
the cause of death attribution system could be refined, 
and multiple causalities permitted.
cOnclusiOns
We have been able to confirm the reproducibility and 
criterion validity of the TRM classification system. We 
believe this supports the hypothesis that the classifica-
tion system can be implemented easily and effectively 
in different healthcare settings, thereby improving 
consistency and accuracy of outcome reporting in 
clinical trials. The TRM classification system will be 
of immense value in the evaluation of deaths in the 
palliative setting. We propose the addition of a sepa-
rate classification tool in patients receiving palliative 
treatment.
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